التفاصيل البيبلوغرافية
| العنوان: |
In vitro and in vivo studies of antiosteosarcoma activities of formononetin. |
| المؤلفون: |
Hu, Wei, Wu, Xianpei, Tang, Jiandong, Xiao, Niansu, Zhao, Guoping, Zhang, Li, Ou, Luanhai |
| المصدر: |
Journal of Cellular Physiology; Oct2019, Vol. 234 Issue 10, p17305-17313, 9p |
| مصطلحات موضوعية: |
FIBRONECTINS, OSTEOSARCOMA, LACTATE dehydrogenase, IN vivo studies, IN vitro studies, BONE cancer |
| مستخلص: |
Osteogenic sarcoma (OGS) is a primary bone cancer, characterized by aggressive neoplasm from mesenchymal oncogenesis. However, the clinical therapeutic regimen against OGS is limited. Therefore, potential medication warrants to be further developed. Our previous study indicates that formononetin (FN) exerts effective pharmacological activity against OGS. This study aimed to further decipher the molecular mechanism behind this benefit. Patients with OGS were recruited for clinical data assay and immunoassay. Human OGS cell line (U2OS) and tumor‐bearing nude mice were subjected to a battery of biochemical analyses and immunoassays for integrative evaluation of FN‐exerted anti‐OGS effects. In human data, OGS samples showed increased expressions of ERα, p‐PI3KCATyr317, and p‐AKT Ser473 proteins, followed by notably upregulated miR‐375 content in comparison with that in OGS‐free. In addition, FN‐treated U2OS cells showed inhibited cell proliferation, elevated lactic dehydrogenase production and lowered endogenous miR‐375 level in cells. Further, reduced immunopositive cells of Ki‐67, p‐PI3KCA Tyr317, and p‐AKT Ser473 were observed by the treatments of FN, while the intracellular Bax‐ and Apaf‐1‐positive cells were increased dose‐dependently. Beneficially, FN‐treated tumor‐bearing mice exhibited reduced tumor mass and intercellular miR‐375 expression. Meanwhile, immuno‐labeled cells and proteins of Bax, Caspase‐3, and Apaf‐1 in FN‐treated mice were increased dose‐dependently, whereas ERα, p‐PI3KCA Tyr317, and p‐AKT Ser473 positive cells and proteins were downregulated, respectively. Collectively, our current results elucidate that FN exerts effective therapeutic benefits against OGS, and the pharmacological mechanism may be related to promoting cell apoptosis by inactivating intracellular miR‐375/ERα−PI3K/AKT cascaded pathway. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Cellular Physiology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
